JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

JP Morgan analyst Priyanka Grover has initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Overweight rating. The firm has set a price target of $75 for the stock.